Baidu
map

Nat Med:埃博拉病毒疫苗rVSV-ZEBOV的多克隆和趋向性抗体反应

2020-07-26 MedSci原创 MedSci原创

重组泡状口炎病毒-扎伊尔埃博拉病毒(rVSV-ZEBOV)是最先进的埃博拉病毒候选疫苗,目前正被用于对抗刚果民主共和国(DRC)爆发的埃博拉病毒病(EVD)。在此,我们通过进行全面的单B细胞和电子显微

重组泡状口炎病毒-扎伊尔埃博拉病毒(rVSV-ZEBOV)是最先进的埃博拉病毒候选疫苗,目前正被用于对抗刚果民主共和国(DRC)爆发的埃博拉病毒病(EVD)。在此,我们通过进行全面的单B细胞和电子显微镜结构分析,研究了参加1期rVSV-ZEBOV疫苗接种试验的人类志愿者子集的体液免疫反应。

4名被研究的疫苗接种者表现出多克隆,但可重复性和趋同的B细胞反应,具有共同的序列特征。EBOV靶向抗体与其他埃博拉病毒种类发生交叉反应,详细的表位图谱显示,目标表位与从EVD幸存者中分离的抗体有重叠。此外,在所有疫苗接种者中,我们检测到了高效力的EBOV中和抗体,其活性与目前临床试验中使用的单克隆抗体相当或更优。这些抗体包括结合IGHV3-15/IGLV1-40免疫球蛋白基因段的抗体,这些抗体在所有被调查的个体中都被发现。

总之,我们的发现将有助于评估和指导当前和未来的疫苗接种策略,并为新型EVD疗法提供机会。

原始出处:

Stefanie A EhrhardtMatthias Zehner, et al., Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nat Med. 2019 Oct;25(10):1589-1600. doi: 10.1038/s41591-019-0602-4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884488, encodeId=7904188448877, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 08:44:13 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083331, encodeId=145d20833317e, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Fri Jan 15 14:44:13 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650385, encodeId=d3a6165038562, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Aug 02 09:44:13 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660221, encodeId=a12d166022107, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sun Sep 27 02:44:13 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296488, encodeId=62b3129648807, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610588, encodeId=fa2d161058815, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-12-21 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884488, encodeId=7904188448877, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 08:44:13 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083331, encodeId=145d20833317e, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Fri Jan 15 14:44:13 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650385, encodeId=d3a6165038562, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Aug 02 09:44:13 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660221, encodeId=a12d166022107, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sun Sep 27 02:44:13 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296488, encodeId=62b3129648807, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610588, encodeId=fa2d161058815, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884488, encodeId=7904188448877, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 08:44:13 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083331, encodeId=145d20833317e, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Fri Jan 15 14:44:13 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650385, encodeId=d3a6165038562, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Aug 02 09:44:13 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660221, encodeId=a12d166022107, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sun Sep 27 02:44:13 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296488, encodeId=62b3129648807, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610588, encodeId=fa2d161058815, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884488, encodeId=7904188448877, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 08:44:13 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083331, encodeId=145d20833317e, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Fri Jan 15 14:44:13 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650385, encodeId=d3a6165038562, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Aug 02 09:44:13 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660221, encodeId=a12d166022107, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sun Sep 27 02:44:13 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296488, encodeId=62b3129648807, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610588, encodeId=fa2d161058815, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-09-27 aids221
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884488, encodeId=7904188448877, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 08:44:13 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083331, encodeId=145d20833317e, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Fri Jan 15 14:44:13 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650385, encodeId=d3a6165038562, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Aug 02 09:44:13 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660221, encodeId=a12d166022107, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sun Sep 27 02:44:13 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296488, encodeId=62b3129648807, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610588, encodeId=fa2d161058815, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1884488, encodeId=7904188448877, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 08:44:13 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083331, encodeId=145d20833317e, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Fri Jan 15 14:44:13 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650385, encodeId=d3a6165038562, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sun Aug 02 09:44:13 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660221, encodeId=a12d166022107, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Sun Sep 27 02:44:13 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296488, encodeId=62b3129648807, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610588, encodeId=fa2d161058815, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 28 07:44:13 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

相关资讯

Pediatrics:接种流感、白喉-破伤风-百日咳和肺炎球菌疫苗后发热

同时接种灭活流感疫苗(IIV)、13价肺炎球菌结合疫苗(PCV13)和白喉-破伤风-百日咳(DTaP)疫苗与接种后发热发作的风险增加有关。本研究中,我们评估了在PCV13和DTaP分开就诊时接种IIV

Lancet:Ad5载体COVID-19疫苗II期临床获得成功

研究认为Ad5载体COVID-19疫苗是安全的,在一次免疫后,大多数受试者都能产生显著的免疫应答

三个月后下降23倍!抗体甚至会消失,新冠疫苗还有用?

目前,全球各国都在紧锣密鼓地研制新冠病毒疫苗,所有人都期盼疫苗研制成功后可以一劳永逸,从新冠病毒的魔爪中解脱出来。然而,近日伦敦国王学院(King’s College London)的一项

NEJM:新冠疫苗mRNA-1273 I期临床效果喜人

mRNA-1273疫苗可诱导健康志愿者产生抗SARS-CoV-2免疫反应,未发现限制试验的安全性问题

NEJM:美国最早启动的新冠疫苗使受试者均产生抗体,预防效果要观后效

新英格兰医学杂志(NEJM)发表了美国最早进入临床试验的COVID-19 mRNA-1273疫苗1期临床试验结果,显示:所有受试者均出现高滴度抗体。

阿斯利康/牛津大学的COVID-19疫苗反应强烈:100%的受试者体内抗体具有中和活性

单剂AZD1222注射后一个月内95%参与者的SARS-CoV-2病毒刺突蛋白抗体增加四倍。

Baidu
map
Baidu
map
Baidu
map